Home > Boards > US Listed > Biotechs >

Intellia Therapeutics Inc. (NTLA)

Add NTLA Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 1/8/2018 1:50:15 PM - Followers: 10 - Board type: Free - Posts Today: 0

Intellia Therapeutics, Inc. is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company's CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing. Its portfolio includes CRISPR/Cas9 platform technology, delivery technologies and nucleic acid modifications for human therapeutic use. The Company's CRISPR/Cas9 platform components include the guide ribonucleic acid (RNA) and the Cas9 nuclease (the genetic scissors). It has access to various delivery modalities specific to various in vivo and ex vivo approaches. The Company focuses on engineering ex vivo CRISPR/Cas9 cell therapies for chimeric antigen receptor T cell (CAR-T) and hematopoietic stem cell (HSC) applications. It also focuses on the use of in vivo Lipid Nanoparticle (LNP) delivery technology.
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NTLA News: Annual Report (10-k) 03/14/2018 08:06:55 AM
NTLA News: Current Report Filing (8-k) 03/14/2018 07:41:52 AM
NTLA News: Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results 03/14/2018 07:30:00 AM
NTLA News: Intellia Therapeutics to Present at March Healthcare Investor Conferences 02/28/2018 04:30:00 PM
NTLA News: Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Ed... 02/27/2018 09:28:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!